Want to join the conversation?
Biopharmaceutical company $ALXN received FDA approvals for Strensiq and Kanuma in 4Q15 under Breakthrough Therapy Designation and received two rare pediatric disease priority review vouchers with the approvals. $ALXN completed enrollment in the DGF registration trial and presented initial data for 3 product candidates in PNH, MPS IIIB and GI-GVHD.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.